Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has been assigned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $36.22.

A number of research firms have recently issued reports on TRHC. William Blair restated an “outperform” rating on shares of Tabula Rasa HealthCare in a research report on Tuesday, March 13th. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Thursday, January 11th. BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd. CIBC restated an “outperform” rating and issued a $47.00 price target (up from $35.00) on shares of Tabula Rasa HealthCare in a research report on Tuesday, March 13th. Finally, Piper Jaffray upped their price target on Tabula Rasa HealthCare to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, March 13th.

How to Become a New Pot Stock Millionaire

In related news, Director Bruce Luehrs sold 252,242 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $34.29, for a total value of $8,649,378.18. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $38.69, for a total value of $309,520.00. The disclosure for this sale can be found here. Insiders sold 324,000 shares of company stock worth $11,309,958 over the last quarter. 45.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hood River Capital Management LLC lifted its holdings in Tabula Rasa HealthCare by 17.1% in the fourth quarter. Hood River Capital Management LLC now owns 883,290 shares of the company’s stock valued at $24,776,000 after acquiring an additional 129,031 shares during the last quarter. Ranger Investment Management L.P. lifted its stake in Tabula Rasa HealthCare by 896.7% during the fourth quarter. Ranger Investment Management L.P. now owns 777,341 shares of the company’s stock worth $21,804,000 after purchasing an additional 699,352 shares in the last quarter. BlackRock Inc. lifted its stake in Tabula Rasa HealthCare by 2.9% during the fourth quarter. BlackRock Inc. now owns 425,027 shares of the company’s stock worth $11,922,000 after purchasing an additional 12,121 shares in the last quarter. Jennison Associates LLC lifted its stake in Tabula Rasa HealthCare by 3.5% during the fourth quarter. Jennison Associates LLC now owns 412,387 shares of the company’s stock worth $11,567,000 after purchasing an additional 13,932 shares in the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new position in Tabula Rasa HealthCare during the fourth quarter worth $9,559,000. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Shares of TRHC stock traded up $0.59 during trading hours on Wednesday, reaching $40.53. The company had a trading volume of 12,817 shares, compared to its average volume of 354,871. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.11 and a current ratio of 1.21. Tabula Rasa HealthCare has a 12-month low of $11.59 and a 12-month high of $41.83.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Monday, March 12th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.03). The company had revenue of $43.93 million during the quarter, compared to analysts’ expectations of $38.91 million. Tabula Rasa HealthCare had a net margin of 10.63% and a negative return on equity of 1.96%. Tabula Rasa HealthCare’s revenue for the quarter was up 60.9% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. equities research analysts predict that Tabula Rasa HealthCare will post 0.18 EPS for the current fiscal year.

WARNING: “Brokerages Set Tabula Rasa HealthCare Inc (TRHC) Target Price at $36.22” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/brokerages-set-tabula-rasa-healthcare-inc-trhc-target-price-at-36-22/2030239.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.